Close
Achema middle east
swop processing & packaging

Clinical Trials

Araclon Biotech Partners with TFS International for Their Alzheimer’s Phase II Trial

After completing a successful phase I partnership with TFS International (TFS), Araclon Biotech a Grifols company, decided to continue the partnership with TFS advancing their...

Biohaven to begin clinical development of BHV-5000 to treat Rett syndrome

Biohaven Pharmaceutical Holding Company Ltd. and its wholly owned subsidiary, Biohaven Pharmaceuticals, Inc., today announced that the U.S. FDA has notified the Company that it...

BioNTech Announces Results from Two More Studies Demonstrating the Benefits of Breast Cancer Subtyping Using Mammatype

BioNTech Diagnostics GmbH is announcing new results from two studies on the MammaTyper® test which were presented at the Breast Cancer Symposium in San Antonio...

Adverum Biotechnologies Doses First Patient in the ADVANCE Phase 1/2 Clinical Trial of ADVM-043 for A1AT Deficiency

Adverum Biotechnologies, Inc , a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced the dosing of the first...

GeNeuro To Receive €12 Million Milestone Payment from Servier for Final Patient Visit in GNbAC1 CHANGE-MS Phase 2b Study

GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, such as multiple sclerosis (MS) and type 1...

Corbus Pharmaceuticals Initiates “RESOLVE-1” Phase 3 Study in Systemic Sclerosis

Corbus Pharmaceuticals Holdings, Inc. , a clinical stage drug development company targeting rare, serious chronic inflammatory and fibrotic diseases, announced that it has initiated the...

Eisai: Updated Analysis of Phase Ib/II Study of Eribulin and Pembrolizumab Combination Regimen

Eisai Co .Ltd. announced that a presentation on the updated analysis of a global Phase Ib/II clinical study (ENHANCE 1 / Study 218) of its...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »